Ranibizumab Biosimilar for Age-related Macular Degeneration

featured image
Therapeutic Areas: Ophthalmology
Year: 2021

Neovascular age-related macular degeneration (nAMD), also known as wet age‐related macular degeneration (wet AMD), is a chronic eye disease characterised by the formation and proliferation of blood vessels underneath the retina (a layer of tissue in the back of the eye that senses light and sends images to the brain). nAMD is a leading cause of central sight loss and blindness.
Ranibizumab biosimilar is a type of antibody that is targeted against a particular protein and administered via injection into the eye (intravitreal injection). Ranibizumab biosimilar has been designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula (the central part of the retina). By blocking VEGF-A, ranibizumab biosimilar would reduce the growth of the blood vessels and control leakage and swelling.